OTHER PUBLICATIONS & ABSTRACTS
Other Data
Evidence / Other
Daily Clinical Practice of Fresh Tumour Tissue Freezing and Gene Expression Profiling; Logistics Pilot Study Preceding the MINDACT Trial
PUBLICATION: Eur J Cancer. 2009 May;45(7):1201-1208. doi: 10.1016/j.ejca.2009.01.004. Epub 2009 Feb 14. AUTHORS: Mook S., Bonnefoi H., Pruneri G., Larsimont D., Jaskiewicz J., Sabadell M.D., MacGrogan G., Van't Veer L.J., Cardoso F., Rutgers E.J. SUMMARY: Tumour samples were obtained in 60 of 64 patients. Among the 60 samples, 11 contained Read More
Constructive Technology Assessment (CTA) as a Tool in Coverage with Evidence Development: The Case of the 70-gene Prognosis Signature for Breast Cancer Diagnostics
PUBLICATION: Int J Technol Assess Health Care. 2009 Jan;25(1):73-83. doi: 10.1017/S0266462309090102. AUTHORS: Retèl V.P., Bueno-de-Mesquita J.M., Hummel M.J., van de Vijver M.J., Douma K.F., Karsenberg K., van Dam F.S., van Krimpen C., Bellot F.E., Roumen R.M., Linn S.C., van Harten W.H. SUMMARY: Differences in speed of implementation and influenced treatment Read More
Robust Interlaboratory Reproducibility of a Gene Expression Signature Measurement Consistent with the Needs of a New Generation of Diagnostic Tools
PUBLICATION: BMC Genomics. 2007 Jun 7;8:148. AUTHORS: Ach R.A., Floore A., Curry B., Lazar V., Glas A.M., Pover R., Tsalenko A., Ripoche H., Cardoso F., d'Assignies M.S., Bruhn L., Van't Veer L.J. SUMMARY: Despite this variation, measurement of one particular breast cancer gene expression signature in three different laboratories was Read More
Converting a Breast Cancer Microarray Signature into a High-Throughput Diagnostic Test
PUBLICATION: BMC Genomics. 2006 Oct 30;7:278. AUTHORS: Glas A.M., Floore A., Delahaye L.J., Witteveen A.T., Pover R.C., Bakx N., Lahti-Domenici J.S., Bruinsma T.J., Warmoes M.O., Bernards R., Wessels L.F., Van't Veer L.J. SUMMARY: In this report, we demonstrate for the first time that microarray technology can be used as a Read More
Gene Expression Profiles of Primary Breast Carcinomas from Patients at High-Risk for Local Recurrence After Breast-Conserving Therapy
PUBLICATION: Clin Cancer Res. 2006 Oct 1;12(19):5705-12. AUTHORS: Kreike B., Halfwerk H., Kristel P., Glas A., Peterse H., Bartelink H., van de Vijver M.J. SUMMARY: No significant differences in gene expression between primary breast cancer tumors in patients with or without local recurrence after BCT were identified. Furthermore, analyses of Read More
Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women with Node-Negative Breast Cancer
PUBLICATION: J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92. AUTHORS: Buyse M., Loi S., van't Veer L., Viale G., Delorenzi M., Glas A.M., d'Assignies M.S., Bergh J., Lidereau R., Ellis P., Harris A., Bogaerts J., Therasse P., Floore A., Amakrane M., Piette F., Rutgers E., Sotiriou C., Cardoso F., Piccart M.J.; Read More
Molecular Portraits and 70-gene Prognosis Signature Are Preserved Throughout the Metastatic Process of Breast Cancer
PUBLICATION: Cancer Res. 2005 Oct 15;65(20):9155-8. AUTHORS: Weigelt B., Hu Z., He X., Livasy C., Carey L.A., Ewend M.G., Glas A.M., Perou C.M., Van't Veer L.J. SUMMARY: Furthermore, our data imply that poor prognosis breast carcinomas classified either by the intrinsic gene set or the 70 prognosis genes represent distinct Read More
